Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Crossref DOI link: https://doi.org/10.1007/s40487-020-00129-x
Published Online: 2021-01-11
Published Print: 2021-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kolberg, Hans-Christian
Demetriou, Georgia Savva
Hanes, Vladimir
Funding for this research was provided by:
Amgen
Text and Data Mining valid from 2021-01-11
Version of Record valid from 2021-01-11
Article History
Received: 26 May 2020
Accepted: 3 July 2020
First Online: 11 January 2021